Loading clinical trials...

Depressed Mood and Anhedonia in Healthy Adults | Clinical Trials | Clareo Health

COMPLETEDNA

Depressed Mood and Anhedonia in Healthy Adults

Chronic Effect of a Standardized Saffron Extract on Depressed Mood and Anhedonia in Healthy Adults. A Randomized Controlled Double-blind Clinical Trial.

NCT05306093•Institut Pasteur de Lille

View on ClinicalTrials.gov

Summary

The aim of this study is to evaluate the effect of nutraceutical supplement on depressed mood and anhedonia in volunteers after 8 weeks of consumption.

Eligibility

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adults aged between 20 and 65 years (limits included);
•Body Mass Index (BMI) ≥19 and \< 30 kg/m²;
•Considered healthy based on their medical history and clinical examination;
•Subjects self-reporting anhedonia based on SHAPS questionnaire. Score ≥ 3 allows the inclusion;
•Subjects with depressive mood disturbance based on POMS depression subscale. Score ≥ 4 allows the inclusion;
•Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form;
•Affiliated with a social security scheme;
•Agreeing to be registered on the national file of the volunteers in biomedical research.

Exclusion Criteria

•Suffer from mental health other than mild depressive or anxiety symptoms as measured by the Patient Health Questionnaire (PHQ-9). Volunteers with PHQ-9 score \>14 could not be included;
•Having suicidal thoughts: score ≥1 at the item 9 of the PHQ-9;
•Diagnosis of medical or psychiatric conditions including (but not limited to):
•* psychiatric disorder (other than mild-to-moderate depression symptoms, anhedonia or anxiety),
•* neurological disease (Parkinson's, Alzheimer's disease, intracranial haemorrhage, head or brain injury),
•* cancer/malignancy,
•* cardiovascular disease (other than hypertension),
•* Immunological disease,
•* endocrine disease (including diabetes or thyroid diseases, Chronic kidney disease, hematological abnormalities);
•Smokers (more than 5 cigarettes per day);
+15 more criteria

Locations (1)

CEN Experimental

Dijon, France

Key Dates

Start Date

January 7, 2022

Primary Completion Date

September 1, 2022

Completion Date

September 1, 2022

Last Updated

September 7, 2022

Enrollment

ACTUAL participants

Conditions

AnhedoniaDepressed Mood

Interventions

Nutraceutical

DIETARY_SUPPLEMENT

Maltodextrin

DIETARY_SUPPLEMENT

Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression

NCT05240352

Anhedonia

View study

RECRUITING

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

NCT07146503

Depression and Quality of LifeTreatment Resistant Depression (TRD)+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Depressed Mood and Anhedonia in Healthy Adults

Inclusion Criteria

Exclusion Criteria

Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

Inflammation and Depression in People With HIV

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

Psilocybin for Treatment-Resistant Depression

Promoting Positive Emotional Functioning in Police and Military Populations